Exocrine pancreatic insufficiency and quality of life after oncologic gastric surgery: Evaluation from a single tertiary center

Table 3 Gastrointestinal Quality of Life Index score according to the clinico-demographic characteristics and exocrine pancreatic insufficiency severity of the study population, n (%)

Variables	Study population (n = 44)	Gastrointestinal Quality of Life Index, median (QR)	P value
Sex
Male	26 (59.1)	85 (76-96)	0.68
Female	18 (40.9)	90 (72-94)
Age
≥ 65	26 (59.1)	83 (66-90)	0.25
< 65	18 (40.9)	90 (76-96)
ASA score
ASA 1	0	0	0.3
ASA 2	36 (81.8)	86 (76-90)
ASA 3	8 (18.2)	93 (66-110)
Neoadjuvant therapy
Yes	25 (56.8)	90 (89-100)	0.23
No	19 (43.2)	85 (72-95)
Type of surgical procedure
STG	26 (59.1)	90 (76-96)	0.53
Total gastrectomy	14 (31.8)	81 (66-95)
Superior polar gastrectomy	4 (9.1)	83 (65-95)
Reconstruction after STG
Roux-en-Y	19 (73.1)	90 (89-96)	0.61
Billroth II	7 (26.9)	79 (76-106)
Clavien-Dindo
≥ 3	4 (9.1)	86 (76-94)	0.82
< 3	40 (90.9)	90 (90-113)
Histotype
Intestinal	23 (52.3)	80 (76-96)	0.6
Diffuse	11 (25)	95 (66-126)
Mixed	10 (22.7)	86 (62-107)
T stage
T1-T2	18 (40.9)	87 (76-95)	0.47
T3-T4	26 (59.1)	88 (71-94)
N stage
N0	19 (43.2)	85 (76-95)	0.41
N+	25 (56.8)	90 (85-105)
EPI
Yes	16 (36.4)	78 (75-106)	0.52
No	28 (63.6)	85 (73-96)
EPI severity
No/moderate	37 (84.1)	89 (84-100)	0.002
Severe	7 (15.9)	65 (59-92)

ASA: American Society of Anesthesiologists; EPI: Exocrine pancreatic insufficiency; QR: Quartile rank; STG: Subtotal gastrectomy.